G1 Pharma (GTHX) - Market Capitalization to Book Value Ratio

Corporate emblem and logo of G1 Therapeutics Inc. (GTHX)

G1 Therapeutics, Inc. (GTHX) is attracting leading biologists for bone marrow protection, which is sparking investor interest. The market capitalization-to-book value ratio illustrates this trend, where 15.19 is the current level of the metric. This is supported by a successful merger with Pharmacosmos under transparent rights and a leadership shift toward a strategy of extracting profit from oncology licensing royalties.

G1 Therapeutics (GTHX) - Market-to-Book Ratio from 07/04/2022 to 09/28/2024
Flagship merchandise of g1therapeutics.com

G1 Therapeutics, Inc. (GTHX) focuses on oncology research without burdening its balance sheet with heavy manufacturing capacities. The multiple is calculated as the ratio of the total market capitalization to the value of net assets. This coefficient determines the premium the market is willing to pay for intellectual capital and future patents. The trend of this indicator signals a shift in the phases of how investors value the business. By analyzing the historical changes in the market-to-book capitalization multiple, one can identify a reversal in the fundamental trend.

Competitor analysis

INCY (Incyte Corporation) - Market Cap to Net Assets Ratio|Capitalization to Book Value Ratio HCM|NUVB (Nuvation Bio) - Market Capitalization to Book Value Ratio|DAWN - Market Value to Equity Ratio|Market Capitalization to Book Value Ratio MNPR|INBX - Market-to-Book Ratio|Market Value to Book Value Ratio I-Mab Biopharma IMAB|FENC: Capitalization to Book Value Ratio|Heron Therapeutics Inc - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Nuvectis Pharma Inc.|Coherus BioSciences (CHRS) - Market Value to Book Value Ratio|Corbus Pharmaceuticals, Inc. - Market Value to Book Value|CRDF (Cardiff Oncology Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio beyondspringpharma.com|Market Value to Book Value Ratio BioAtla, Inc. (BCAB)|Market Value to Book Value Ratio LIXT (Lixte Biotechnology Holdings Inc.)|Citius Pharmaceuticals, Inc. - Market Cap to Net Assets Ratio|Market Value to Book Value CLRB|BLRX - Market Value to Book Value Ratio|Market-to-Book Ratio canfite.com|aprea.com (APRE) - Market Value to Book Value Ratio|Capitalization to Book Value Ratio KZIA|SLXN (Silexion Therapeutics Corp.) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio NuCana Corp (NCNA)|Market Value to Book Value Ratio Chimerix, Inc. (CMRX)|CYCC - Market-to-Book Ratio|Market Value to Book Value Ratio Kronos Bio KRON|Kintara Therapeutics Inc - Market Value to Book Value Ratio|ONCT - Market Value to Book Value Ratio|Market-to-Book Ratio Portage Biotech Corp